focus -WSS

focus

author：hotspot 2025-10-01 07:42:03 - browse：6

Scientist Nour Tabidi prepares a DNA sample in a lab. -- health coverage from STAT — Scientist Nour Tabidi prepares a DNA sample in a lab at Thermo Fisher's recently opened manufacturing plant in Plainville. John Tlumacki/Globe Staff

Thermo Fisher Scientific’s giant plant to manufacture gene therapies for drug companies is barely a year old, but executives at the maker of scientific tools are already talking about expanding.

Standing inside a cavernous unfinished section of the plant, Paul Fitzgerald, vice president and general manager of the site, told a group of biotech executives, journalists, and other visitors that he’s eager to transform it into laboratories. So far, the company is only using about 290,000 of the plant’s more than 400,000 square feet.

“I look forward to you guys giving us a reason to fill up this space,” Fitzgerald quipped during a tour Tuesday of the plant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Why scientists need input from humanists on sensitive research

knowledge

WSS

Why depression after traumatic brain injury is distinct

Male and female sex labels in research insufficient, scientists say

Medicare coverage of Wegovy, once blocked, now looks possible

Key House Republican on health care plans exit from Congress

Robert F. Kennedy is pitching centrism on health, even on abortion

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Wikipedia

focus

explore

Drug repurposing or repositioning? The language matters

UCLA team creates talking throat patch for voice disorders

How one medical school became remarkably diverse

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

How to save PrEP access — and even expand it

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare Advantage proposed rates disappoint insurers

Dobbs anniversary: the lost opportunity of abortion as health care

Industry veterans launch new biotech VC with $310M

focus

Readout LOUD podcast: How biotech is using artificial intelligence

Medicare Advantage proposed rates disappoint insurers

Boston's new lab space is opening empty

What should King Charles tell the public about his cancer?

The dental labor crisis is a moment of opportunity

Biogen Alzheimer’s drug launch off to slow start

focus

focus

knowledge

focus